PRODUCTS SOLD BY ASCEND PEPTIDES ARE INTENDED FOR RESEARCH USE ONLY.
Laboratory research material
Ipamorelin 10mg research peptide is the 10mg format of ipamorelin, a GHS-R1a (ghrelin receptor) agonist pentapeptide, for laboratory programmes requiring larger compound quantities and multi-arm study designs. Janoshik report published for a tested batch. Same working-day UK dispatch on in-stock orders before 3pm (Mon–Fri). For research use only.
Research guides: What Is Ipamorelin? · GHRH analogues vs GHRPs
Safety Information: Not intended for human or veterinary use. Use appropriate laboratory safety procedures when handling.
IPAMORELIN 10mg should only be used in laboratory settings by qualified personnel.
Ensure all experimental procedures comply with local and institutional regulations.
This peptide is supplied for research and scientific study purposes only.
Ipamorelin 10 mg:
View Janoshik report #125389 (tested sample: Ipamorelin 10mg)
This report covers one tested sample. It does not establish that current stock comes from the same batch.
Ipamorelin 10mg Research Peptide UK
Ipamorelin 10mg is the larger-format version of Ipamorelin 5mg. Identical compound to Ipamorelin 5mg in every respect — synthetic pentapeptide, C38H49N9O5, molecular weight 711.85 g/mol, GHS-R1a agonist — supplied in a larger quantity for full concentration-response gradients, multi-arm experimental designs and longer single-batch studies.
The research case for the ipamorelin 10mg format builds on programme maturity. Once the 5mg pilot phase has validated assay conditions, confirmed receptor response, and established the experimental design, the 10mg format provides consistent compound supply across multiple arms or extended time points without the inter-batch variability that comes from sourcing multiple 5mg vials. For first-time ipamorelin research and a complete guide to the mechanism of action, see the Ipamorelin research guide on the Ascend Peptides UK blog, which covers both formats in detail.
When paired with CJC-1295 Without DAC 10mg, the two compounds act at different receptors: ipamorelin at GHS-R1a and CJC-1295 at GHRHR. Both increase GH release, and combined GHRH and GHRP stimulation can interact, so in the same experimental system they are not independent variables and combined arms need appropriate controls.
For researchers studying downstream effects of GH axis stimulation, IGF-1 LR3 1mg provides the growth factor research tool for the downstream GH-IGF-1 signalling cascade, operating through the IGF-1 receptor (IGF-1R) rather than the ghrelin or GHRH receptor pathways.
Evidence status: besides the original animal studies, ipamorelin has been tested in humans. In a randomised, placebo-controlled phase 2 trial in 114 patients after bowel resection, intravenous ipamorelin was well tolerated, but the difference in time to tolerating solid food was not statistically significant (Beck et al., Int J Colorectal Dis, 2014). It has not been approved as a medicine. These data do not describe or verify the research material supplied here.
An Ipamorelin 10mg batch has been independently tested by Janoshik. Its batch-specific Certificate of Analysis reports measured content and purity and is available for independent verification. LC-MS identity data is not separately reported on the published certificate.
Prohibited at all times (ipamorelin is named on the WADA Prohibited List as a ghrelin mimetic under S2).
For in-vitro research only. Not an MHRA-licensed medicine.
Other laboratory research materials supplied by Ascend Peptides UK.
UK same working-day dispatch – Secure payment options –
Laboratory research only
© 2026 by Ascend Peptides Uk.
All products sold by Ascend Peptides UK are intended strictly for laboratory research purposes only. Not intended for human consumption or therapeutic use of any kind.
Per product, applied automatically in your bagAuto-applied in your bag
Ordering more? Contact us for larger-volume pricing →